HMP Global May 29, 2025
In this interview, Josh Canavan, PharmD, head of pharmacy at RazorMetrics, discusses rising specialty drug costs, payer challenges in biosimilar adoption, the importance of seamless prescriber engagement, data-driven approaches to formulary optimization, and emerging trends such as polypharmacy and member cost burden identified in the 2025 State of Drug Access report.
Josh Canavan, PharmD: Hi, I’m Josh Canavan. I’m the head of pharmacy at RazorMetrics. I’ve been here since about 2018. I’ve been a pharmacist for over 20 years now. I’ve worked in retail and hospital. I on worked electronic health record (EHR) implementation and support. I’ve done I work with pharmacy benefit managers (PBMs) to help manage formularies, and now my main role is working with our clinical team—which...
Today's Sponsors
Today's Sponsor